VEGFR2/CD309 Antikörper
Kurzübersicht für VEGFR2/CD309 Antikörper (ABIN2664545)
Target
Alle VEGFR2/CD309 (VEGFR2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- The antibody was purified by affinity chromatography.
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.5 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Andere Bezeichnung
- CD309
-
Hintergrund
- CD309, also known as VEGF-R2, KDR, and Flk-1 (mouse), is a type I transmembrane glycoprotein. It is a member of the CSF-1/PDGF receptor family of type III tyrosine kinase receptors. Human VEGF-R2 is mainly expressed by endothelial cells, embryonic tissues, and megakaryocytes. It plays an important role in the regulation of angiogenesis, vasculogenesis, and vascular permeability. The ligands of VEGF-R2 include VEGF-A, VEGF-C, and VEGF-D splice isoforms. Activation of VEGF-R2 with its ligands results in the receptor dimerization and autophosphorylation, stimulating endothelial cell proliferation and migration.
-
Pathways
- RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Target
-